InvestorsHub Logo
Post# of 249855
Next 10
Followers 789
Posts 118584
Boards Moderated 15
Alias Born 09/05/2002

Re: jbog post# 243322

Friday, 07/29/2022 8:34:55 AM

Friday, July 29, 2022 8:34:55 AM

Post# of 249855
ENTA’s PR on EDP-235 phase-1/1b data:

Based on these positive safety and PK results, ENTA is advancing the 200mg qD and 400mg qD doses (without ritonavir boosting) to phase-2, which is expected to start in 4Q22.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.